Eyenovia provides clinical and scientific update on fda-approved products mydcombi™ and clobetasol propionate ophthalmic suspension

Company announces results from a phase iv study of mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8Μl spray per eye)

EYEN Ratings Summary

EYEN Quant Ranking